Enovis (ENOV) Competitors $46.38 +0.81 (+1.78%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ENOV vs. PEN, GKOS, BLCO, INSP, PRCT, AXNX, NVST, TMDX, NARI, and LIVNShould you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Penumbra (PEN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Axonics (AXNX), Envista (NVST), TransMedics Group (TMDX), Inari Medical (NARI), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. Enovis vs. Penumbra Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Axonics Envista TransMedics Group Inari Medical LivaNova Penumbra (NYSE:PEN) and Enovis (NYSE:ENOV) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Is PEN or ENOV more profitable? Penumbra has a net margin of 2.97% compared to Enovis' net margin of -5.95%. Penumbra's return on equity of 8.99% beat Enovis' return on equity.Company Net Margins Return on Equity Return on Assets Penumbra2.97% 8.99% 6.80% Enovis -5.95%4.39%2.80% Which has stronger earnings and valuation, PEN or ENOV? Penumbra has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPenumbra$1.06B8.62$90.95M$0.86276.56Enovis$1.71B1.52-$33.26M-$2.19-21.18 Does the MarketBeat Community believe in PEN or ENOV? Penumbra received 784 more outperform votes than Enovis when rated by MarketBeat users. Likewise, 80.26% of users gave Penumbra an outperform vote while only 61.70% of users gave Enovis an outperform vote. CompanyUnderperformOutperformPenumbraOutperform Votes81380.26% Underperform Votes20019.74%EnovisOutperform Votes2961.70% Underperform Votes1838.30% Does the media prefer PEN or ENOV? In the previous week, Enovis had 6 more articles in the media than Penumbra. MarketBeat recorded 12 mentions for Enovis and 6 mentions for Penumbra. Enovis' average media sentiment score of 0.71 beat Penumbra's score of 0.35 indicating that Enovis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Enovis 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, PEN or ENOV? Penumbra has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Do institutionals & insiders have more ownership in PEN or ENOV? 88.9% of Penumbra shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 5.0% of Penumbra shares are owned by insiders. Comparatively, 2.4% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend PEN or ENOV? Penumbra presently has a consensus price target of $226.67, indicating a potential downside of 4.70%. Enovis has a consensus price target of $67.00, indicating a potential upside of 44.46%. Given Enovis' stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than Penumbra.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Penumbra 0 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.71Enovis 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 SummaryPenumbra beats Enovis on 11 of the 18 factors compared between the two stocks. Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get Enovis News Delivered to You Automatically Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENOV vs. The Competition Export to ExcelMetricEnovisSurgical appliances & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$2.59B$9.56B$5.13B$19.80BDividend YieldN/A1.09%5.18%3.51%P/E Ratio-21.1815.3866.7335.39Price / Sales1.5230.541,265.2917.78Price / Cash7.2523.4740.2121.45Price / Book0.784.576.454.64Net Income-$33.26M$182.72M$119.73M$982.94M7 Day Performance-0.09%-4.58%-5.13%-2.12%1 Month Performance12.96%-6.59%-2.71%-0.39%1 Year Performance-9.41%-1.32%31.08%23.34% Enovis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENOVEnovis3.2486 of 5 stars$46.38+1.8%$67.00+44.5%-8.8%$2.59B$1.71B-21.186,550Short Interest ↑PENPenumbra4.1989 of 5 stars$236.41+0.1%N/A+6.3%$9.07B$1.06B274.904,200GKOSGlaukos3.7551 of 5 stars$145.45+1.3%N/A+113.7%$8.02B$314.71M-48.16780Upcoming EarningsShort Interest ↑BLCOBausch + Lomb2.4489 of 5 stars$19.51-0.2%N/A+25.4%$6.87B$4.15B-18.5813,300Short Interest ↓INSPInspire Medical Systems4.9216 of 5 stars$190.58-0.1%N/A+20.5%$5.71B$624.80M178.111,011Positive NewsPRCTPROCEPT BioRobotics2.559 of 5 stars$96.31+0.8%N/A+165.7%$5.03B$136.19M-49.39626Analyst ForecastAXNXAxonics3.1036 of 5 stars$70.470.0%N/AN/A$3.60B$366.38M-587.20610Short Interest ↑News CoverageNVSTEnvista3.6878 of 5 stars$20.55+0.1%N/A-10.9%$3.54B$2.57B-2.6412,800Short Interest ↓TMDXTransMedics Group4.4922 of 5 stars$95.94+5.0%N/A+20.6%$3.22B$241.62M102.06210Short Interest ↑NARIInari Medical3.3224 of 5 stars$51.07-0.4%N/A-14.3%$2.99B$493.63M-37.831,300Positive NewsLIVNLivaNova4.0095 of 5 stars$53.42+0.8%N/A+10.3%$2.90B$1.15B127.192,900Analyst ForecastNews Coverage Related Companies and Tools Related Companies Penumbra Competitors Glaukos Competitors Bausch + Lomb Competitors Inspire Medical Systems Competitors PROCEPT BioRobotics Competitors Axonics Competitors Envista Competitors TransMedics Group Competitors Inari Medical Competitors LivaNova Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ENOV) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENOV Stock Alerts